LncRNA FEZF1-AS1 Modulates Cancer Stem Cell Properties of Human Gastric Cancer Through MiR-363-3p/HMGA2

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2020 Jul 9

PMID 32638620

Citations 18

Authors

Yuanjian Hui

Yan Yang

Deping Li

Juan Wang

Maojun Di

Shichao Zhang

Shasha Wang

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is a leading cause of cancer-related death with poor prognosis. Growing evidence has shown that long noncoding ribonucleic acid (lncRNA) FEZ family zinc finger 1 antisense RNA 1(FEZF1-AS1), an "oncogene," regulates tumor progression and supports cancer stem cell. However, the tumorigenic mechanism of FEZF1-AS1 on gastric cancer stem cell (GCSC) is yet to be investigated. Here, we discovered that FEZF1-AS1 was upregulated in GC tissues and cell lines. Knockdown of FEZF1-AS1 inhibited sphere formation and decreased expression of stem factors and markers. Moreover, FEZF1-AS1 silence also suppressed cell proliferation, viability, invasion, and migration of GCSCs. MiR-363-3p is used as a target of FEZF1-AS1, because its expression was suppressed by FEZF1-AS1 in GCSCs. FEZF1-AS1 could sponge miR-363-3p and increased the expression of high-mobility group AT-hook 2 (HMGA2). The expression of FEZF1-AS1 and miR-363-3p, as well as that of miR-363-3p and HMGA2, was negatively correlated in GC tissues. Finally, FEZF1-AS1 contributed to promotion of GCSCs progression partially through inhibition of miR-363-3p. Subcutaneous xenotransplanted tumor model revealed that silence of FEZF1-AS1 suppressed in vivo tumorigenic ability of GSCS via downregulation of HMGA2. In general, our findings clarified the critical regulatory role of FEZF1-AS1/miR-363-3p/HMGA2 axis in GCSC progression, providing a potential therapeutic target for GC.

Citing Articles

Theoretical perspectives and clinical applications of non-coding RNA in lung cancer metastasis: a systematic review.

Yang J, Luo Y, Yao Z, Wang Z, Jiang K Discov Oncol. 2025; 16(1):169.

PMID: 39937377 PMC: 11822152. DOI: 10.1007/s12672-025-01919-3.

LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance.

Elimam H, Moussa R, Radwan A, Hatawsh A, Elfar N, Alhamshry N Funct Integr Genomics. 2024; 24(5):175.

PMID: 39325107 DOI: 10.1007/s10142-024-01450-8.

METTL3-Regulated lncRNA SNHG7 Drives MNNG-Induced Epithelial-Mesenchymal Transition in Gastric Precancerous Lesions.

Jian J, Feng Y, Wang R, Li C, Zhang L, Ruan Y Toxics. 2024; 12(8).

PMID: 39195675 PMC: 11360688. DOI: 10.3390/toxics12080573.

The role of EZH2 and its regulatory lncRNAs as a serum-based biomarker in Alzheimer's disease.

Dibaj M, Haghi M, Safaralizadeh R, Saberi A Mol Biol Rep. 2024; 51(1):866.

PMID: 39073683 DOI: 10.1007/s11033-024-09802-0.

LncRNA FEZF1-AS1 facilitates cisplatin resistance in non-small cell lung cancer through modulating the miR-32-5p-glutaminase axis.

Lin W, Wu W, Liang Z, Zhang J, Fang S Am J Cancer Res. 2024; 14(6):3153-3170.

PMID: 39005663 PMC: 11236770. DOI: 10.62347/WUKN6549.

References

Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J . LncRNA-FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling. Clin Cancer Res. 2018; 24(19):4808-4819. DOI: 10.1158/1078-0432.CCR-17-2967. View

Yang Z, Wang J, Liu S, Li X, Miao L, Yang B . Defeating relapsed and refractory malignancies through a nano-enabled mitochondria-mediated respiratory inhibition and damage pathway. Biomaterials. 2019; 229:119580. DOI: 10.1016/j.biomaterials.2019.119580. View

Huang K, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan A . Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell. 2018; 33(1):137-150.e5. DOI: 10.1016/j.ccell.2017.11.018. View

Song H, Xu Y, Shi L, Xu T, Fan R, Cao M . LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability. Biomed Pharmacother. 2018; 108:338-346. DOI: 10.1016/j.biopha.2018.09.057. View

Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M . Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008; 14(8):2334-40. DOI: 10.1158/1078-0432.CCR-07-4667. View

Saito T, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M . A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer. Ann Surg Oncol. 2015; 22 Suppl 3:S915-22. DOI: 10.1245/s10434-015-4554-8. View

Rahman R, Asombang A, Ibdah J . Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20(16):4483-90. PMC: 4000485. DOI: 10.3748/wjg.v20.i16.4483. View

Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y . Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2013; 31(1):358-64. DOI: 10.3892/or.2013.2850. View

Yang Z, Wang J, Ai S, Sun J, Mai X, Guan W . Self-generating oxygen enhanced mitochondrion-targeted photodynamic therapy for tumor treatment with hypoxia scavenging. Theranostics. 2019; 9(23):6809-6823. PMC: 6815961. DOI: 10.7150/thno.36988. View

10.

Gu Y, Chen T, Li G, Yu X, Lu Y, Wang H . LncRNAs: emerging biomarkers in gastric cancer. Future Oncol. 2015; 11(17):2427-41. DOI: 10.2217/fon.15.175. View

11.

Chen J, Wu P, Xia R, Yang J, Huo X, Gu D . STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018; 17(1):6. PMC: 5767073. DOI: 10.1186/s12943-017-0756-y. View

12.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

13.

Chen F, Tian Y, Pang E, Wang Y, Li L . MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer. Cancer Gene Ther. 2015; . DOI: 10.1038/cgt.2015.6. View

14.

Lu L, Dai Z, Luo Q, Lv G . The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma. Mol Med Rep. 2017; 17(1):1947-1953. DOI: 10.3892/mmr.2017.8080. View

15.

Wang J, Liang H, Ge H, Guo X, Gu D, Yuan Y . MicroRNA‑363‑3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage. Mol Med Rep. 2018; 19(2):935-942. PMC: 6323225. DOI: 10.3892/mmr.2018.9711. View

16.

Rassouli F, Matin M, Saeinasab M . Cancer stem cells in human digestive tract malignancies. Tumour Biol. 2015; 37(1):7-21. DOI: 10.1007/s13277-015-4155-y. View

17.

Yong X, Tang B, Xiao Y, Xie R, Qin Y, Luo G . Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett. 2016; 374(2):292-303. DOI: 10.1016/j.canlet.2016.02.032. View

18.

Sreepadmanabh M, Toley B . Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics. Biotechnol Adv. 2018; 36(4):1094-1110. DOI: 10.1016/j.biotechadv.2018.03.009. View

19.

Wu X, Zhang P, Zhu H, Li S, Chen X, Shi L . Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway. Biomed Pharmacother. 2017; 96:1103-1108. DOI: 10.1016/j.biopha.2017.11.113. View

20.

Jeong M, Park S, Lee S, Seo J, Yoo J, Park S . EPB41L5 Mediates TGFβ-Induced Metastasis of Gastric Cancer. Clin Cancer Res. 2019; 25(12):3617-3629. DOI: 10.1158/1078-0432.CCR-18-2959. View